These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Profile of sarilumab and its potential in the treatment of rheumatoid arthritis. Raimondo MG; Biggioggero M; Crotti C; Becciolini A; Favalli EG Drug Des Devel Ther; 2017; 11():1593-1603. PubMed ID: 28579757 [TBL] [Abstract][Full Text] [Related]
3. Spotlight on sirukumab for the treatment of rheumatoid arthritis: the evidence to date. Lazzerini PE; Capecchi PL; Guidelli GM; Selvi E; Acampa M; Laghi-Pasini F Drug Des Devel Ther; 2016; 10():3083-3098. PubMed ID: 27713619 [TBL] [Abstract][Full Text] [Related]
4. Tocilizumab in the treatment of rheumatoid arthritis and beyond. Shetty A; Hanson R; Korsten P; Shawagfeh M; Arami S; Volkov S; Vila O; Swedler W; Shunaigat AN; Smadi S; Sawaqed R; Perkins D; Shahrara S; Sweiss NJ Drug Des Devel Ther; 2014; 8():349-64. PubMed ID: 24729685 [TBL] [Abstract][Full Text] [Related]
6. The role of tocilizumab in the management of rheumatoid arthritis. Ash Z; Emery P Expert Opin Biol Ther; 2012 Sep; 12(9):1277-89. PubMed ID: 22849354 [TBL] [Abstract][Full Text] [Related]
7. Consensus statement on blocking the effects of interleukin-6 and in particular by interleukin-6 receptor inhibition in rheumatoid arthritis and other inflammatory conditions. Smolen JS; Schoels MM; Nishimoto N; Breedveld FC; Burmester GR; Dougados M; Emery P; Ferraccioli G; Gabay C; Gibofsky A; Gomez-Reino JJ; Jones G; Kvien TK; Murakami M; Betteridge N; Bingham CO; Bykerk V; Choy EH; Combe B; Cutolo M; Graninger W; Lanas A; Martin-Mola E; Montecucco C; Ostergaard M; Pavelka K; Rubbert-Roth A; Sattar N; Scholte-Voshaar M; Tanaka Y; Trauner M; Valentini G; Winthrop KL; de Wit M; van der Heijde D Ann Rheum Dis; 2013 Apr; 72(4):482-92. PubMed ID: 23172750 [TBL] [Abstract][Full Text] [Related]
8. Comparison of tocilizumab monotherapy versus methotrexate monotherapy in patients with moderate to severe rheumatoid arthritis: the AMBITION study. Jones G; Sebba A; Gu J; Lowenstein MB; Calvo A; Gomez-Reino JJ; Siri DA; Tomsic M; Alecock E; Woodworth T; Genovese MC Ann Rheum Dis; 2010 Jan; 69(1):88-96. PubMed ID: 19297346 [TBL] [Abstract][Full Text] [Related]
9. Double-blind randomized controlled clinical trial of the interleukin-6 receptor antagonist, tocilizumab, in European patients with rheumatoid arthritis who had an incomplete response to methotrexate. Maini RN; Taylor PC; Szechinski J; Pavelka K; Bröll J; Balint G; Emery P; Raemen F; Petersen J; Smolen J; Thomson D; Kishimoto T; Arthritis Rheum; 2006 Sep; 54(9):2817-29. PubMed ID: 16947782 [TBL] [Abstract][Full Text] [Related]
10. Tocilizumab: a review of its use in the management of rheumatoid arthritis. Oldfield V; Dhillon S; Plosker GL Drugs; 2009; 69(5):609-32. PubMed ID: 19368420 [TBL] [Abstract][Full Text] [Related]
11. Clinical value of blocking IL-6 receptor. Mima T; Nishimoto N Curr Opin Rheumatol; 2009 May; 21(3):224-30. PubMed ID: 19365268 [TBL] [Abstract][Full Text] [Related]
12. Room for more IL-6 blockade? Sarilumab for the treatment of rheumatoid arthritis. June RR; Olsen NJ Expert Opin Biol Ther; 2016 Oct; 16(10):1303-9. PubMed ID: 27464017 [TBL] [Abstract][Full Text] [Related]
13. Comparative effectiveness of biologics for the management of rheumatoid arthritis: systematic review and network meta-analysis. Alfonso-Cristancho R; Armstrong N; Arjunji R; Riemsma R; Worthy G; Ganguly R; Kleijnen J Clin Rheumatol; 2017 Jan; 36(1):25-34. PubMed ID: 27726046 [TBL] [Abstract][Full Text] [Related]
14. New biologics for rheumatoid arthritis. Choy E J R Coll Physicians Edinb; 2011 Sep; 41(3):234-7. PubMed ID: 21949922 [TBL] [Abstract][Full Text] [Related]
15. Tocilizumab for treating rheumatoid arthritis: an evaluation of pharmacokinetics/pharmacodynamics and clinical efficacy. Song SN; Yoshizaki K Expert Opin Drug Metab Toxicol; 2015 Feb; 11(2):307-16. PubMed ID: 25491492 [TBL] [Abstract][Full Text] [Related]
16. Targeting IL-6 for the treatment of rheumatoid arthritis: Phase II investigational drugs. Semerano L; Thiolat A; Minichiello E; Clavel G; Bessis N; Boissier MC Expert Opin Investig Drugs; 2014 Jul; 23(7):979-99. PubMed ID: 24766460 [TBL] [Abstract][Full Text] [Related]
17. Subcutaneous Tocilizumab Is Effective for Treatment of Elderly-Onset Rheumatoid Arthritis. Kondo N; Fujisawa J; Endo N Tohoku J Exp Med; 2020 May; 251(1):9-18. PubMed ID: 32404541 [TBL] [Abstract][Full Text] [Related]
18. Tocilizumab: A Review in Rheumatoid Arthritis. Scott LJ Drugs; 2017 Nov; 77(17):1865-1879. PubMed ID: 29094311 [TBL] [Abstract][Full Text] [Related]
19. [The efficacy and safety of tocilizumab combined with disease-modifying anti-rheumatoid drugs in the treatment of active rheumatoid arthritis: a multi-center, randomized, double-blinded, placebo-controlled trial]. Shi Q; Zhao Y; Bao CD; Li XF; Huang F; Zhu P; Li ZG; Gu JR; Zhang ZY; Zhao DB; Zhao SL; Jiang QD; Tian J; Zhang FC Zhonghua Nei Ke Za Zhi; 2013 Apr; 52(4):323-9. PubMed ID: 23925361 [TBL] [Abstract][Full Text] [Related]
20. Interleukin-6 inhibition for treatment of rheumatoid arthritis: a review of tocilizumab therapy. Patel AM; Moreland LW Drug Des Devel Ther; 2010 Oct; 4():263-78. PubMed ID: 21116333 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]